HASBROUCK HEIGHTS, N.J., March 11, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2009. Nymox reported a net loss of $5,130,074, or $0.17 per share for the year ended December 31, 2009, compared to $4,637,103, or $0.16 per share for same period in 2008. The increase of the net loss for the year is attributable to expenses relating to the launch of Phase 3 clinical trials for NX-1207. Net losses include stock compensation charges of $1,085,164 in 2009 and $925,220 in 2008. Product sales amounted to $415,980 for the year ended December 31, 2009, compared to $426,675 for the same period in 2008. The weighted average number of common shares at the year ended December 31, 2009 was 30,717,822, compared to 29,749,000 at December 31, 2008.
Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company's new drug for benign prostatic hyperplasia (BPH) is in Phase 3 development. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. Nymox has a number of drugs in development for other indications such as E. coli infection, Alzheimer's disease, oncology, and infectious disease. The Company offers NicAlertTM and TobacAlertTM tests for measuring tobacco product exposure, and AlzheimAlert TM, a test to aid in the diagnosis of Alzheimer's disease.
More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.